Jens Okkels - Ascendis Pharma VP Devel
| A1SN34 Stock | BRL 53.35 0.00 0.00% |
Insider
Jens Okkels is VP Devel of Ascendis Pharma AS
| Age | 62 |
| Phone | 45 70 22 22 44 |
| Web | https://ascendispharma.com |
Ascendis Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2658) % which means that it has lost $0.2658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6669) %, meaning that it generated substantial loss on money invested by shareholders. Ascendis Pharma's management efficiency ratios could be used to measure how well Ascendis Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Oyler | BeiGene | 55 | |
| David Altshuler | Vertex Pharmaceuticals Incorpor | 53 | |
| Sean Marett | BIONTECH SE DRN | 58 | |
| Michael Parini | Vertex Pharmaceuticals Incorpor | 43 | |
| Jerh Collins | Moderna | N/A | |
| Alan Garber | Vertex Pharmaceuticals Incorpor | 62 | |
| Chan Lee | BeiGene | N/A | |
| Lavina CFA | Moderna | N/A | |
| Jeffrey MD | Vertex Pharmaceuticals Incorpor | 67 | |
| Xiaobin Wu | BeiGene | 61 | |
| Stephen MD | Moderna | 47 | |
| Stuart Arbuckle | Vertex Pharmaceuticals Incorpor | 53 | |
| Kristen Ambrose | Vertex Pharmaceuticals Incorpor | 46 | |
| Julia Wang | BeiGene | 52 | |
| Francisco Costa | Biomm SA | N/A | |
| Noubar Afeyan | Moderna | 60 | |
| Damian Esq | Vertex Pharmaceuticals Incorpor | 47 | |
| Lloyd Carney | Vertex Pharmaceuticals Incorpor | 57 | |
| Jeffrey Leiden | Vertex Pharmaceuticals Incorpor | 63 | |
| John Gray | Vertex Pharmaceuticals Incorpor | 53 | |
| Terrence Kearney | Vertex Pharmaceuticals Incorpor | 64 | |
Management Performance
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 |
Ascendis Pharma AS Leadership Team
Elected by the shareholders, the Ascendis Pharma's board of directors comprises two types of representatives: Ascendis Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascendis. The board's role is to monitor Ascendis Pharma's management team and ensure that shareholders' interests are well served. Ascendis Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascendis Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Flemming Jensen, VP Quality | ||
| Scott Smith, Sr CFO | ||
| Michael LLM, Chief VP | ||
| Jan Mikkelsen, CEO and President | ||
| Birgitte MD, Sr Affairs | ||
| Timothy Lee, Director Relations | ||
| Lotte Sonderbjerg, Sr Officer | ||
| Peter Rasmussen, VP Officer | ||
| Kennett Sprogoe, VP Research | ||
| Jens Okkels, VP Devel |
Ascendis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascendis Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (15.89) % | |||
| Current Valuation | 34.82 B | |||
| Shares Outstanding | 57.03 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 1,080 X | |||
| Revenue | 7.78 M | |||
| Gross Profit | 4.25 M | |||
| EBITDA | (364.64 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.